PERT

Vizient Medical Device Tech Watch Highlights Trends in AI, Treatment Options for Pulmonary Embolism and Strategies to Boost Clinical Workforce Retention

Retrieved on: 
Tuesday, September 6, 2022
Technology, Health, Human Resources, Other Health, Consulting, Pharmaceutical, Professional Services, Artificial Intelligence, Practice Management, Medical Devices, General Health, Hospitals, Cardiology, Medical Supplies, Machine learning, Patient, Workforce, Research, Technology, COVID-19, Artificial intelligence, Solution, Pathology, Physician, Radiology, Intelligence, Deep learning, Pulmonary embolism, Collaboration, Risk, PERT, Growth, AI, Adoption, Health, Medical device, Medicine, Vizient, Inc.

Vizient, Inc. today released its latest Medical Device Tech Watch, identifying trends in artificial intelligence (AI), examining treatment options for pulmonary embolism and highlighting strategies to boost clinical workforce retention.

Key Points: 
  • Vizient, Inc. today released its latest Medical Device Tech Watch, identifying trends in artificial intelligence (AI), examining treatment options for pulmonary embolism and highlighting strategies to boost clinical workforce retention.
  • Through Tech Watch, Vizient provides clinical updates and operational strategies that help healthcare providers optimize care delivery and operational efficiencies, and lower costs.
  • Collaboration and technology advances are improving pulmonary embolism treatment and outcomes While the pandemic continues to fluctuate, the risk of pulmonary embolism (PE) associated with COVID-19 infection remains.
  • A pulmonary embolism response team (PERT) can enable rapid clinical coordination of care and improved outcomes in PE patients.

Report - Lack of French-Language training opportunities for professional orders contributes to labour market shortage

Retrieved on: 
Monday, July 18, 2022
PERT, GLOBE, Language, Government, Employment, OQLF, Property management, Medicine, Management

The report highlights the shortcomings in the current state of French-language training support offered to members of professional orders in Qubec.

Key Points: 
  • The report highlights the shortcomings in the current state of French-language training support offered to members of professional orders in Qubec.
  • We fear this will further exacerbate the current labour shortage, says Nicholas Salter, Executive Director, Provincital Employment Rountable (PERT).
  • The province is currently in the midst of a labour shortage, with 37,120 vacant positions in the fields of healthcare and social assistance.
  • There is a desire within professional orders for more organizational capacity and funding to improve their training programs and provide French-language support.

Grace Wins Chemical Week’s Innovation Award for ActivCat® Catalyst

Retrieved on: 
Wednesday, May 18, 2022
Research and development, Economics, Public health, Climate change, Atomic mass, PP, Food, Regional Centre of Advanced Technologies and Materials, Grace, Solution, IHS Markit, Trust, Lists of disasters, Forward-looking statement, Compliance, Polyethylene, Standard Industries, Technology, William Russell Grace, PERT, Development, Reuters - The World's Most Innovative Universities, Recycling, GLOBE, Chemical, Fine chemical, Research

COLUMBIA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- W. R. Grace & Co. (Grace), the leading independent supplier of polyolefin catalyst technology and polypropylene (PP) technology, has won the 2022 Chemical Week Global Innovation Award for the Most Innovative Specialty Chemicals Sustainable Product for their groundbreaking ActivCat catalyst.

Key Points: 
  • COLUMBIA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- W. R. Grace & Co. (Grace), the leading independent supplier of polyolefin catalyst technology and polypropylene (PP) technology, has won the 2022 Chemical Week Global Innovation Award for the Most Innovative Specialty Chemicals Sustainable Product for their groundbreaking ActivCat catalyst.
  • Being recognized for a revolutionary product innovation like ActivCat catalyst, spotlights Graces dedication to finding sustainable solutions to address the global need for renewable materials.
  • She adds, Reducing plastic pollution globally while creating recyclable solutions, ActivCat catalyst technology addresses both challenges.
  • The Chemical Week Specialty Chemicals Sustainable Product Innovation Award recognizes the best sustainable product innovation in the specialty chemical space that is commercially manufactured and has had a significant milestone in its development within the past five years.

ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

Retrieved on: 
Friday, May 13, 2022
NSF, Company, Stanford University, U.S. Securities and Exchange Commission, Patient, DOD, NASDAQ, Depression, NIH, San Francisco, FDA, FreeMind, CNS, University of California, San Francisco, Forward-looking statement, Cedars-Sinai Medical Center, University, Technology, Risk, Pancreatic cancer, Ophthalmology, PERT, SEC, Cancer, Security (finance), CA, BARDA, GLOBE, Pharmaceutical industry

FreeMind has a knowledgeable and experienced team of project managers with the ability to help ABVC identify the most suitable grant opportunities and assist in preparing and submitting the applications.

Key Points: 
  • FreeMind has a knowledgeable and experienced team of project managers with the ability to help ABVC identify the most suitable grant opportunities and assist in preparing and submitting the applications.
  • Over the last 10 years, their work has helped their clients to receive over $1.7 billion in non-dilutive funding.
  • We are hopeful that this collaboration will allow us to fund more of our promising clinical trials from non-dilutive capital sources, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)

Retrieved on: 
Tuesday, May 10, 2022
Transfer, Artery, Solution, Thrombectomy, Company, Stroke, Safety, Data, Leg, Patient, Pulmonary embolism, Thrombus, BGU, Aarhus University Hospital, FIH, Ben-Gurion University of the Negev, Breathe Me, BIOMED, PE, Prognosis, Efficiency, PERT, Embolism, Technology, CEO, Association of British HealthTech Industries, Medical imaging, Pharmaceutical industry, Computer data storage, Birth control, Magneto, Incentive

OR YEHUDA, Israel, May 10, 2022 /PRNewswire/ -- Magneto Thrombectomy Solutions (Magneto), a medical devices company developing innovative thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism, presented today successful first-in-human (FIH) results showing safety and feasibility of the eTrieve™ system, a novel catheter based on electric fields for removing blood clots, in patients with acute pulmonary embolism (PE). The data, presented today at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel (May 10-12, Tel Aviv), showed a significant reduction in RV/LV ratio and alleviation of PE associated symptoms.

Key Points: 
  • "We are very pleased with our FIH results, which confirm the safety and efficiency of our innovative technology, as previously demonstrated in preclinical studies," said Benny Dilmoney, CEO of Magneto.
  • "Our novel catheter is a groundbreaking solution that can transform treatment of conditions caused by blood clots, such as pulmonary embolism.
  • PE is a rapidly growing market enhanced by the Pulmonary Embolism Response Team (PERT) approach for PE management.
  • Magneto Thrombectomy Solutions is developing innovative thrombectomy solutions for the treatment of ischemic strokes and pulmonary embolisms.

Report: Limited amount of workplace French-language training programs for English speakers further exacerbates Québec’s labour market shortage

Retrieved on: 
Tuesday, April 12, 2022
Program, Employment, PERT, Government, GLOBE, Â, Health insurance, Management

PERTs report highlights the difficulties English-speaking Quebecers experience when trying to access FLWPs in order to enter, re-join or advance in the labour market.

Key Points: 
  • PERTs report highlights the difficulties English-speaking Quebecers experience when trying to access FLWPs in order to enter, re-join or advance in the labour market.
  • PERTs report points to issues related to program availability, accessibility and regional disparities as limiting opportunities for Qubec's English speakers to gain a level of French proficiency that would help them succeed in the labour market.
  • This is an even bigger problem given the labour market shortage Qubec is experiencing, said Nicholas Salter, Executive Director of PERT.
  • Now, more than ever, we need to ensure English speakers are given the tools to fully contribute to Qubecs economy, said Mr. Salter.

Shutdowns, Turnarounds and Outages Online Master Class (April 5th-8th, 2022) - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022
Other Manufacturing, Technology, Professional Services, Manufacturing, Software, Other Education, Training, Other Professional Services, Education, Checklist, Review, CPM, Basics, PERT, Gantt, Shutdown, Half Day, Illinois, Compact Disc, Management, Medicine

The "Shutdowns, Turnarounds and Outages Master Class" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Shutdowns, Turnarounds and Outages Master Class" training has been added to ResearchAndMarkets.com's offering.
  • This course is specially designed to let you have a new and deeper understanding of how to effectively manage shutdowns and turnarounds such as plant outages and refits etc.
  • Each student will receive and review a master checklist developed over the last 20 years of items that have caused problems on past shutdowns.
  • Mastering the Basics of Shutdowns, Turnarounds, and Outages
    Is the Shutdown a cover-up?

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

Retrieved on: 
Thursday, January 13, 2022
PERT, Nature, Patient, International, Stomach, Niclosamide, Clinical trial, Fats, Weight loss, BOCA, Diarrhea, Nutrient, Malabsorption, NASDAQ, EPI, CEO, Absorption, Cystic Fibrosis Foundation, GLOBE, Standard of care, Cystic fibrosis, Ulcerative colitis, U.S. Securities and Exchange Commission, Acquisition, USPTO, Program, Patent, Company, Method, Digestion, Food, Yarrowia, INN, Steatorrhea, First wave, Lipase, Security (finance), Abdominal pain, Exocrine pancreatic insufficiency, International nonproprietary name, FW, Medical imaging, Pharmaceutical industry

BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.

Key Points: 
  • BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.
  • First Wave BioPharma has filed two new provisional patent applications pertaining to adrulipase with the U.S. Patent and Trademark Office (USPTO).
  • This is an important step in our efforts to strengthen and expand our adrulipase intellectual property portfolio as we advance the FW-EPI clinical development program, said James Sapirstein, President and CEO of First Wave BioPharma.
  • First Wave BioPharma is pursuing parallel monotherapy and combination therapy clinical pathways with adrulipase.

New online community to provide important support to chronic pancreatitis patients.

Retrieved on: 
Tuesday, November 16, 2021
Health, Industry, Therapy, PERT, Chronic pancreatitis, Pancreatitis, CEO, Disease, HealthUnlocked, SVP, Research, Acute pancreatitis, LLC, Patient, Food, NHS, National Health Service (England), Pancreas, Steatorrhea, EPI, EU, Pharmaceutical industry

The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment.

Key Points: 
  • The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment.
  • Patients can join the community by following this link: https://healthunlocked.com/pancreatitis-support
    "Chronic pancreatitis is a chronic inflammatory destructive disease of the pancreas associated with multiple consequences including pancreatic exocrine insufficiency.
  • "Aimmune is committed to further understanding the impact of EPI on the quality of patients' lives with chronic pancreatitis," said Mohamed Yassine, MD.
  • Clinicians, the NHS (including NHS Choices), insurers and industry can use HealthUnlocked to link up with patients safely online.

Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

Retrieved on: 
Wednesday, November 3, 2021
Safety, Science, Degenerative disease, Pancreatic cancer, Research, Exocrine pancreatic insufficiency, Protein engineering, Stomach, Enzyme, Partnership, Medicine, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, Food, SEC, Synthetic biology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Adult, Annual report, PK, Cystic fibrosis, Steatorrhea, PERT, CEO, Complementarity, Pharmacokinetics, Health, EPI, Therapy, GLOBE, Codexis, Pancreatitis, Â, Pharmaceutical industry, Fine chemical

Our partnership with Nestl Health Science aims at leveraging the CodeEvolver protein engineering platform to create novel orally administered enzyme therapies for patients.

Key Points: 
  • Our partnership with Nestl Health Science aims at leveraging the CodeEvolver protein engineering platform to create novel orally administered enzyme therapies for patients.
  • We are excited to advance the first candidate from this partnership, CDX-7108, into clinical development, according to John Nicols, Codexis President and CEO.
  • The goal of our strategic collaboration is to offer an effective new treatment for people who suffer from exocrine pancreatic insufficiency, said Hans-Juergen Woerle, Chief Scientific and Medical Officer at Nestl Health Science.
  • Nestl Health Science is a leader in the science of nutrition and a globally managed business unit of Nestl.